Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 2/2012

01-04-2012 | Review Article

Metabolic syndrome: its history, mechanisms, and limitations

Author: Eiji Oda

Published in: Acta Diabetologica | Issue 2/2012

Login to get access

Abstract

In late twentieth century, Ruderman and Reaven showed that insulin resistance might be fundamental to metabolic syndrome (MetS) which means a constellation of obesity-related metabolic derangements predisposing to type 2 diabetes and cardiovascular disease. In 2001, user-friendly National Cholesterol Education Program (NCEP) criteria of MetS were proposed. In 2005, the International Diabetes Federation (IDF) and the Examination Committee for Criteria of Metabolic Syndrome in Japan issued different criteria of MetS where abdominal obesity is a necessary component. In 2009, IDF, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity jointly adopted the revised NCEP criteria, where abdominal obesity is not a necessary component, as worldwide criteria of MetS. In 2010, WHO Expert Consultation warned that MetS is a concept that focuses attention on complex multifactorial health problems but has limited practical utility as a management tool. In animal studies, adipose tissue inflammation characterized by an increased number of crown-like structures in adipose tissue, rather than obesity per se, was shown to be a fundamental mechanism of metabolic derangements.
Literature
1.
2.
World Health Organization (1999) Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO Consultation. World Health Org, Geneva
3.
Expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 285:2486–2497
4.
Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome―a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23:469–480PubMedCrossRef
5.
Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American heart association/National heart, lung, and blood institute scientific statement. Circulation 112:2735–2752PubMedCrossRef
6.
Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and International association for the study of obesity. Circulation 120:1640–1645PubMedCrossRef
7.
Matsuzawa YM (1997) Pathophysiology and molecular mechanism of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev 13:3–13PubMedCrossRef
8.
The Examination Committee for Criteria of Metabolic Syndrome (2005) Definition and criteria of metabolic syndrome. J Jpn Soc Intern Med 94:794–809 (in Japanese)CrossRef
9.
Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care 28:2289–2304PubMedCrossRef
10.
Simmons RK, Alberti KG, Gale EA et al (2010) The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53:600–605PubMedCrossRef
11.
Oda E (2008) The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 31:1283–1291PubMedCrossRef
12.
Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347–2355PubMedCrossRef
13.
Vague J (1956) The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, uric calculous disease. Am J Clin Nutr 4:20–34PubMed
14.
Ruderman NB, Schneider SH, Berchtold P (1981) The “metabolically-obese”, normal-weight individual. Am J Clin Nutr 34:1617–1621PubMed
15.
Kissebah AH, Vydelingum N, Murray R et al (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54:254–260PubMedCrossRef
16.
Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S (1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54–59PubMedCrossRef
17.
Ferrannini E, Buzzigoli G, Bonadonna R et al (1987) Insulin resistance in essential hypertension. N Engl J Med 317:350–357PubMedCrossRef
18.
Kaplan (1989) The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514–1520
19.
DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194PubMedCrossRef
20.
Lemieux I, Pascot A, Couillard C et al (2000) Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102:179–184PubMed
21.
Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European group for the study of insulin resistance (EGIR). Diabet Med 16:442–443PubMedCrossRef
22.
Einhorn D, Reaven GM, Cobin RH et al (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252PubMed
23.
Ridker PM, Wilson PWF, Grandy SM (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818–2825PubMedCrossRef
24.
Reaven GM (2006) The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 83:1237–1247PubMed
25.
Klein S, Allison DB, Heymsfield SB et al (2007) Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care 30:1647–1652PubMedCrossRef
26.
Fox CS, Massaro JM, Hoffmann U et al (2007) Abdominal visceral and subcutaneous adipose tissue compartments. Association with metabolic risk factors in the Framingham Heart Study. Circulation 116:39–48PubMedCrossRef
27.
Pou KM, Massaro JM, Hoffmann U et al (2007) Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. The Framingham Heart Study. Circulation 116:1234–1241PubMedCrossRef
28.
Fox CS, Hwang S-J, Massaro JM et al (2009) Relation of subcutaneous and visceral adipose tissue to coronary and abdominal aortic calcium (from the Framingham Heart Study). Am J Cardiol 104:543–547PubMedCrossRef
29.
Herrera MF, Pantoja JP, Velázquez-Fernández D et al (2010) Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in Grade III obese patients undergoing Laparoscopic Roux-en-Y gastric bypass. A randomized trial. Diabetes Care 33:1413–1418PubMedCrossRef
30.
Oda E, Kawai R (2011) Changes in body weight are significantly associated with changes in fasting plasma glucose and HDL cholesterol in Japanese men without abdominal obesity (waist circumference <85 cm). Acta Diabetol 48:143–148PubMedCrossRef
31.
Kadota A, Hozawa A, Okamura T et al (2007) Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990–2000. Diabetes Care 30:1533–1538PubMedCrossRef
32.
Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S (2009) Metabolic syndrome and all-cause and cardiovascular disease mortality: Japan Public Health Center-based Prospective (JPHC) Study. Circ J 73:878–884PubMedCrossRef
33.
Noda H, Iso H, Saito I et al (2009) The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: Japan public health center-based study. Hypertens Res 32:289–298PubMedCrossRef
34.
Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87–91PubMedCrossRef
35.
Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93:12490–12495PubMedCrossRef
36.
Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100:2158–2169PubMedCrossRef
37.
Federici M, Hribal ML, Menghini R et al (2005) Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115:3494–3505PubMedCrossRef
38.
Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52:2169–2181PubMedCrossRef
39.
Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I (2008) CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol 129:815–822PubMedCrossRef
40.
41.
Kolak M, Westerbacka J, Velagapudi VR et al (2007) Adipose tissue inflammation and increased ceramide content characterized subjects with high liver fat content independent of obesity. Diabetes 56:1960–1968PubMedCrossRef
42.
Katagiri H, Yamada T, Oka Y (2007) Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 101:27–39PubMedCrossRef
43.
Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448–1454PubMedCrossRef
44.
Kim J, Montagnani M, Koh KK, Quon MJ (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 113:1888–1904PubMedCrossRef
45.
Bains RK, Wells SE, Flavell DM et al (2004) Visceral obesity without insulin resistance in late-onset obesity rats. Endocrinology 145:2666–2679PubMedCrossRef
46.
Kanda H, Tateya S, Tamori Y et al (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494–1505PubMedCrossRef
47.
Kamei N, Tobe K, Suzuki R et al (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissue causes macrophage recruitment and insulin resistance. J Biol Chem 281:26602–26614PubMedCrossRef
48.
Kim JY, Wall E, Laplante M et al (2007) Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117:2621–2637PubMedCrossRef
49.
Strissel KJ, Stancheva Z, Miyoshi H et al (2007) Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 56:2910–2918PubMedCrossRef
50.
Oda E, Kawai R (2010) Comparison among body mass index (BMI), waist circumference (WC), and percent body fat (%BF) as anthropometric markers for the clustering of metabolic risk factors in Japanese. Intern Med 49:1477–1482PubMedCrossRef
51.
Oda E, Kawai R (2010) Body mass index is more strongly associated with hypertension than waist circumference in apparently healthy Japanese men and women. Acta Diabetol 47:309–313PubMedCrossRef
52.
The emerging risk factors collaboration (2011) Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 377:1085–1095
53.
Salminen M, Kuoppamäki M, Vahlberg T, Räihä I, Irjala K, Kivelä SL (2011) Metabolic syndrome and vascular risk: a 9-year follow-up among the aged in Finland. Acta Diabetol 48:157–165PubMedCrossRef
54.
Ertek S, Cicero AF, Cesur M et al (2011) The severity of coronary atherosclerosis in diabetic and nondiabetic metabolic syndrome patients diagnosed according to different criteria and undergoing elective angiography. Acta Diabetol 48:21–27PubMedCrossRef
55.
Fadini GP, de Kreutzenberg SV, Gjini R, Avogaro A (2011) The metabolic syndrome influences the response to incretin-based therapies. Acta Diabetol. May 15. [Epub ahead of print] PubMed PMID: 21574000
56.
Ruan W, Lai M (2010) Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol 47:5–14PubMedCrossRef
57.
Oda E, Kawai R (2009) Comparison between high-sensitivity C-reactive protein (hs-CRP) and white blood cell count (WBC) as an inflammatory component of metabolic syndrome in Japanese. Intern Med 49:117–124CrossRef
58.
Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38PubMedCrossRef
59.
Hanley AJG, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM (2005) Liver markers and development of the metabolic syndrome. The insulin resistance atherosclerosis study. Diabetes 54:3140–3147PubMedCrossRef
60.
Lee DS, Evans JC, Robins SJ et al (2007) Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham heart study. Arterioscler Thromb Vasc Biol 27:127–133PubMedCrossRef
61.
Halimi JM, Bonnet F, Lange C et al (2008) Urinary albumin excretion is a risk factor for diabetes mellitus in men, independently of initial metabolic profile and development of insulin resistance. The DESIR Study. J Hypertens 26:2096–2100CrossRef
62.
Brantsma AH, Bakker SJL, Hillege HL et al (2005) Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 28:2525–2530PubMedCrossRef
63.
Monami M, Pala L, Bardini G et al (2009) Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) Study. Acta Diabetol 46:191–196PubMedCrossRef
64.
Luk AO, So WY, Ma RC et al (2008) Metabolic syndrome predicts new onset of chronic kidney disease in 5829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care 31:2357–2361PubMedCrossRef
65.
Kurella M, Lo JC, Chertow GM (2005) Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16:2134–2140PubMedCrossRef
66.
Lucove J, Yupputuri S, Heiss G et al (2008) Metabolic syndrome and the development of CKD in American Indians: the strong heart study. Am J Kidney Dis 51:21–28PubMedCrossRef
67.
Esteghamati A, Rashidi A, Khalilzadeh O, Ashraf H, Abbasi M (2010) Metabolic syndrome is independently associated with microalbuminuria in type 2 diabetes. Acta Diabetol 47:125–130PubMedCrossRef
68.
Yeh H, Punjabi NM, Wang N, Pankow JS, Duncan BB, Brancati FL (2005) Vital capacity as a predictor of incident type 2 diabetes. The atherosclerosis risk in communities study. Diabetes Care 28:1472–1479PubMedCrossRef
69.
Oda E, Kawai R (2009) A cross-sectional relationship between vital capacity and diabetes in Japanese men. Diabetes Res Clin Pract 85:111–116PubMedCrossRef
70.
Oda E, Kawai R (2009) Significance of heart rate on the prevalence of metabolic syndrome and its related risk factors in Japanese. Circ J 73:1431–1436PubMedCrossRef
71.
Fox K, Borer JS, Camm AJ et al (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50:823–830PubMedCrossRef
72.
Metadata
Title
Metabolic syndrome: its history, mechanisms, and limitations
Author
Eiji Oda
Publication date
01-04-2012
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 2/2012
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0309-6

Other articles of this Issue 2/2012

Acta Diabetologica 2/2012 Go to the issue

Original Article

Impaired diffusing capacity for carbon monoxide in children with type 1 diabetes: is this the first sign of long-term complications?

Original Article

The development of a sleep apnea screening program in Romanian type 2 diabetic patients: a pilot study

Erratum

Erratum to: Impaired diffusing capacity for carbon monoxide in children with type 1 diabetes: is this the first sign of long-term complications?

Original Article

Kidney function and retinol status in type 2 diabetes mellitus patients

Original Article

Markedly increased serum and urinary fructose concentrations in diabetic patients with ketoacidosis or ketosis

Original Article

Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits